Search

Search Constraints

You searched for: Author/Creator Meylan, Maxime

Search Results

1. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Issue 5 (May 2022)

2. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Issue 2 (16th October 2020)

3. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Issue 2 (16th October 2020)

4. TMIC-10. IDENTIFICATION, VALIDATION AND BIOLOGICAL CHARACTERIZATION OF NOVEL GLIOBLASTOMA TUMOUR MICROENVIRONMENT SUBTYPES: IMPLICATIONS FOR PRECISION IMMUNOTHERAPY. (14th November 2022)

6. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. Issue 5 (31st May 2022)

7. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Issue 2 (16th October 2020)

8. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Issue 2 (16th October 2020)

9. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Issue 2 (16th October 2020)

10. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. Issue 2 (16th October 2020)